Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference
Werte in diesem Artikel
SECAUCUS, N.J., Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024, at 3:00 p.m. Eastern Time.
The fireside chat and Q&A session will be webcast live during the conference and will be available on the company's investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until January 3, 2025.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-speak-at-the-7th-annual-evercore-healthconx-conference-302321119.html
SOURCE Quest Diagnostics
Ausgewählte Hebelprodukte auf Quest Diagnostics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Quest Diagnostics
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Quest Diagnostics Inc.
Analysen zu Quest Diagnostics Inc.
Datum | Rating | Analyst | |
---|---|---|---|
25.06.2018 | Quest Diagnostics Overweight | Barclays Capital | |
20.10.2017 | Quest Diagnostics Buy | Mizuho | |
25.07.2017 | Quest Diagnostics Buy | Mizuho | |
05.06.2017 | Quest Diagnostics Buy | Mizuho | |
12.05.2017 | Quest Diagnostics Hold | Argus Research Company |
Datum | Rating | Analyst | |
---|---|---|---|
25.06.2018 | Quest Diagnostics Overweight | Barclays Capital | |
20.10.2017 | Quest Diagnostics Buy | Mizuho | |
25.07.2017 | Quest Diagnostics Buy | Mizuho | |
05.06.2017 | Quest Diagnostics Buy | Mizuho | |
26.04.2017 | Quest Diagnostics Buy | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
12.05.2017 | Quest Diagnostics Hold | Argus Research Company | |
07.03.2017 | Quest Diagnostics Equal Weight | Barclays Capital | |
21.10.2016 | Quest Diagnostics Neutral | Mizuho | |
22.04.2016 | Quest Diagnostics Equal Weight | Barclays Capital | |
22.04.2016 | Quest Diagnostics Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quest Diagnostics Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen